Pulmonx Q3 2026 Earnings Conference Call - PULMONX CORP

Financial Performance:

• Total worldwide revenue reached $22.8 million in Q3 2026, a 6% year-over-year increase, marking the return to global growth since leadership restructuring.
• U.S. revenue grew 7% year-over-year to $14.9 million; International revenue grew 5% year-over-year to $7.9 million, excluding a 9% growth in non-China international markets.
• Gross margin improved to 76% in Q3 2026 from 75% in the prior year, driven by reduced distributor mix in international markets and supply chain efficiencies; full-year 2026 gross margin is expected to be approximately 77%.
• Total operating expenses decreased 18% year-over-year to $24.9 million, with SG&A down 22% to $20 million and R&D rising slightly to $4.9 million.
• Net loss narrowed 40% year-over-year to $8.4 million ($0.19/share) compared to $14 million ($0.34/share) in the prior period.
• Adjusted EBITDA loss improved significantly by nearly 60% to $3.5 million in Q3 2026 from $8.2 million in the prior year.
• Ending cash and cash equivalents were $52.7 million; full-year 2026 cash burn is expected to be approximately $22 million, a 30% reduction from 2025.
• Credit facility restructuring extends debt maturity to 2031 with access to an additional $20 million in undrawn capital subject to revenue milestones.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance is reiterated at $90–$92 million.
• Full-year 2026 operating expenses are expected to range between $108–$109 million, inclusive of ~$14 million in non-cash stock-based compensation.
• Management expects Q4 2026 to maintain sequential growth momentum, potentially exiting 2026 with double-digit growth rates.
• No specific 2027 guidance is provided; management remains committed to sustaining double-digit growth long-term but deems it premature to set a specific timeline.
• China shipments are expected to resume in early 2027 (potentially late Q4 2026), representing ~2% of total business; full China impact is expected to be more lumpy due to the distributor model.
• AeroSeal commercial launch is planned for Europe in 2027, with material revenue contribution expected in 2028.
• Cash flow break-even is viewed as a clear long-term pathway driven by top-line growth and operating leverage, assuming gross margins remain above 75%.

Business Segments and Product Lines:

• U.S. Commercial: Sales leadership team is substantially rebuilt with open territories filled; focus on "near-to-far" strategy emphasizing high-quality valve programs, physician education, and direct-to-patient efforts in geographies with established centers.
• International: Strong growth outside of China (9%); 99% of current business is direct; China is a distributor market.
• Product Expansion: AeroSeal (TAM expansion tool) expected to grow the addressable market by ~20% globally; Convert2 IDE trial enrollment on track for completion in the back half of 2027.
• Clinical Data: Positive reception at European Respiratory Society Congress regarding bronchoscopic lung volume reduction and multidisciplinary approaches; LIBERATE trial 5-year follow-up data presented at AABIP.
• Account Growth: Added eight new U.S. treating centers; targeting ~40 new accounts annually, currently tracking ahead of this goal.

Market and Competitive Landscape:

• Market focus remains on severe COPD management and bronchoscopic lung volume reduction, with significant scientific interest in patient pathways and experience.
• Competitive positioning strengthened through the "near-to-far" framework, prioritizing existing accounts (same-store sales) and reactivating dormant accounts over solely chasing new logos.
• Internal success stories show promoted junior Territory Account Managers (TAMs) leading regional growth, indicating high efficacy of the current training and promotion model.
• Addressable market expansion is projected at 20% globally via AeroSeal, primarily targeting European markets for the initial commercial rollout.

Risks and Challenges:

• China Market: Regulatory delays and tariff discussions previously impacted revenue; the distributor model introduces variability and lumpy revenue streams compared to direct markets.
• Salesforce Tenure: Average sales team tenure is currently on the junior side (median 1.2 years), creating variability in ramp-up speed, though promotion of internal junior reps is proving successful.
• Execution Risk: Future growth relies heavily on the successful ramp-up of the rebuilt sales team and the execution of the refocused commercial strategy.
• Clinical Timelines: Reliance on AeroSeal (Convert2 IDE) enrollment completion in the second half of 2027 for future market expansion.

Management Commentary and Tone:

• Tone is highly confident and optimistic, emphasizing the successful execution of the turnaround strategy and a return to revenue growth.
• Management expressed strong conviction in the rebuilt foundation, citing broad-based activity increases and improved operational leverage.
• Emphasis was placed on disciplined cost management, having reduced recurring costs by 10% without cutting commercial or R&D investments.
• Management indicated comfort with the current cost structure, expecting only minor inflationary increases in OPEX moving forward.

Analyst Questions and Answers:

• Growth Drivers (Canaccord): Q3 growth was sequential and beat seasonality; attributed to filled territories, executing procedures, and improved rep productivity rather than a single specific factor.
• Salesforce Productivity (Canaccord): Tenure is short (median 1.2 years), but promoted internal reps are outperforming; training adjustments and "running starts" for junior reps are showing success.
• 2027 Outlook (Jefferies): Management declined to provide 2027 guidance details but confirmed commitment to double-digit growth; clarified China is a ~2% business segment and AeroSeal revenue in Europe will be limited in 2027, expanding in 2028.
• Territory Expansion (Jefferies): Territory expansion will remain opportunistic based on revenue complexity or geographic breadth; modest increases expected.
• New vs. Reactivated Accounts (Piper Sandler): Strategy balances ~40 new accounts/year with a primary focus on same-store sales; new reps are successfully reactivating dormant accounts.
• Cash Flow/Cash Burn (Piper Sandler): Cash burn reduction is expected to continue in 2027 and beyond, driven by operating leverage from top-line growth rather than further cost cutting; path to cash break-even remains clear.

Other Key Points:

• The company has successfully reduced stock-based compensation expense to $3.2 million in Q3 2026.
• Revenue in China represented a peak of 10% of total revenue in a prior quarter due to regulatory prep, but is currently normalized at ~3% of global revenue (with 99% direct mix).
• Management highlighted the "near-to-far" market development framework as the core driver for the recent sequential U.S. growth.
• The organization has filled substantially all open U.S. sales positions since the start of the year.